What is GRIT Biotechnology?
Founded in 2019 and headquartered in Shanghai, China, GRIT Biotechnology is dedicated to advancing novel biotherapeutics. The company's core focus lies in the development of Tumor Infiltrating Lymphocytes (TIL) therapies, a cutting-edge approach in cancer treatment. This strategic direction positions GRIT Biotechnology at the forefront of immuno-oncology innovation, aiming to provide more effective and targeted treatment options for patients.
How much funding has GRIT Biotechnology raised?
GRIT Biotechnology has raised a total of $60M across 1 funding round:
Series B
$60M
Series B (2023): $60M with participation from China International Capital, Yuanhe Capital, and Qianhai Ark
Key Investors in GRIT Biotechnology
China International Capital
China International Capital (CICC) is a leading financial services firm established in 1995, offering a comprehensive suite of investment banking, equities, and wealth management services. With a strong presence in China and international operations, CICC provides strategic financial backing to growth-stage companies.
Yuanhe Capital
Yuanhe Capital is an investment entity that participates in significant funding rounds, contributing capital to companies poised for expansion and market leadership.
Qianhai Ark
Qianhai Ark is an investment firm known for its strategic involvement in promising ventures, providing crucial financial support to drive innovation and growth within its portfolio companies.
What's next for GRIT Biotechnology?
The substantial enterprise-level funding, particularly the recent Series B financing, signals a critical growth phase for GRIT Biotechnology. This capital infusion is expected to accelerate the company's research and development initiatives, potentially expanding its clinical trial pipeline and enhancing its manufacturing capabilities. The strategic backing suggests a strong market confidence in GRIT Biotechnology's TIL therapy platform and its potential to disrupt the oncology market, paving the way for future commercialization and broader patient access.
See full GRIT Biotechnology company page
